A Phase 1 interventional study of LY3305677 and Placebo in Overweight and Obesity, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-05.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing mazdutide in Obesity — 11 open to participants now, 14 under way, 4 of them phase 3. mazdutide · Obesity.
Among the 22 studies testing mazdutide in Obesity, this one is the 20th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 1, and was the 5th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →11 of the 22 studies testing mazdutide in Obesity are open now, in 3 countries. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
China-Japan Friendship Hospital · Sites in China
Ages 18–60
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18+
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 12–18
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, mazdutide is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 6 · Phase 4 2
First in 2020; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 187 across the 22 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 22 have an industry lead sponsor. The 8 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 109th largest by enrollment of the 117 interventional ones that give a count, is one of 10 that started in 2022, is one of 40 in phase 1, and was the 25th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
3 of the studies testing mazdutide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06931028Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 | 2027-05-07 |
| NCT07255209Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study of IBI362 in Chinese Adolescents With Obesity or Overweight | 2027-10-31 |
| NCT06143956Eli Lilly and CompanyA Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies testing mazdutide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3305677 or placebo given just under the skin. For each participant, the study will last about approximately 28 weeks.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 32 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY3305677 administered subcutaneously (SC)
Drug: LY3305677
Placebo administered SC
Drug: Placebo
Administered SC
Administered SC
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline through Week 20
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3305677
PK: Cmax of LY3305677
Time frame: Predose up to 72 hours postdose
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3305677
PK: AUC of LY3305677
Time frame: Predose up to 72 hours postdose
Pharmacodynamics (PD): Percentage change in Body Weight
PD: Percentage change in Body Weight
Time frame: Baseline through Week 20
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2022 to primary completion in Jun 2023, 7 months.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mazdutide